Head-to-head evidence
Aripiprazole (Abilify) vs Aripiprazole (Abilify Maintena)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole (Abilify)
Marketed by Otsuka Holdings and partners
NCT00712686 · Phase 3 · completed
The study was a large randomized, double-blind, active-controlled trial comparing aripiprazole with olanzapine, with 690 participants. However, the registry provides no results for either primary endpoint, so it is not possible to determine whether the primary comparisons were favorable or statistically significant.
Next expected readout: September 2027 · NCT07547384 (registry estimate)
Aripiprazole (Abilify Maintena)
Marketed by Otsuka Holdings and partners
NCT00706654 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 662 randomized maintenance-phase participants, including 265 assigned to depot 300/400 mg and 266 to oral aripiprazole. The primary clinical relapse endpoint was met: depot treatment was non-inferior to oral aripiprazole, with a difference of -0.64 percentage points and a 95% confidence interval of -5.26 to 3.99, below the prespecified 11.5% margin.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify)'s landscape · Aripiprazole (Abilify Maintena)'s landscape